search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Business


Table 4: Skills required for Pharma R&D Data Science44 A strong educational background. 88% of data scientists have a Master’s degree and 46% have PhDs


TYPICAL DATA SCIENTIST TASKS


Collecting large amounts of structured and unstructured data and transforming it into a usable analytics-ready format


Solving business problems using data-driven techniques


Staying on top of analytical techniques such as machine learning, deep learning and text analytics, including benchmarking of methods


BUSINESS SKILLS


Domain Knowledge such as molecular biology, medicinal chemistry, clinical R&D, regulatory affairs, epidemiology, pharmaco-economics


Intellectual curiosity, creative problem-solving and strategic thinking


Relevant business acumen and awareness of industry trends


TECHNICAL SKILLS REQUIRED IN THE YEAR 2020


R Programming (43% of data scientists use R)


Medical statistics/pharmaceutical statistics45


Procedural and compiler coding Database query languages: SQL SPARQL Data modelling in relational and RDF form


Communicating and collaborating with both IT and the business


Looking for order and patterns in data, as well as spotting trends that generate value


Validating models and analyses


Communication skills to different levels of audience


Relationship-building, teamwork and conflict resolution


Understanding of legal, regulatory and ethical issues


Familiarity with cloud-based environments (AWS, Google, Microsoft)


Data visualisation techniques Machine Learning and AI


Text mining and related ontology use in semantic based text mining


In the early 2020s, many organisations suffered


delays in their R&D programmes due to a shortage of relevant skills. Today, the executive leadership of the biopharmaceutical industry has widely recognised the importance of the technology-biolo- gy interface to innovation. R&D IT – or R&D Technology as it has increasingly become known – is now seen as a strategic discipline and, important- ly, different from the traditional IT that supports line of business activities. Management has largely accepted that the rate


of change of the technology-science continuum is so rapid that extra effort has to be expended to keep the workforce’s skills up-to-date. As such, increased investment in training, development and education kept up-skilling personnel, allowing new technologies to be brought in without causing unnecessary redundancies in the workforce. Such training curricula were provided in large part by external organisations such as universities, eg Oxford University’s MSc in ‘Nanotechnology for Medicine and Health Care’37, or Harvard’s ‘CRISPR: Gene-editing Applications’38, or the Pistoia Alliance’s globally-recognised educational programmes,


including its member-driven ‘Technology Observatory’, which keeps members 46


up-to-date on emerging trends in life science and healthcare. In 2017, PhRMA commissioned a report


addressing efforts to attract and grow the biophar- maceutical industry39 and the availability of STEM skills. In 2018, the ABPI had produced a report entitled ‘Bridging the skills gap in the biopharma- ceutical industry’40. Digital experts needed to be encouraged to join


the biopharma industry and biopharma needed to compete against other industry sectors, such as the well-funded FinTech, as every company was fishing in the same limited talent pool. One of the key hur- dles to overcome in recruiting talented young peo- ple was the negative perception held by society of the biopharma industry, caused by many serious and on-going issues to do with transparency (for example Humphrey Rang’s review of Ben Goldacre’s book Bad Pharma: how drug compa- nies mislead doctors and harm patients41), and problems of pricing42. As highlighted in the PwC Pharma 2005, 2010


and 2020 reports, the perception that society had of the pharmaceutical industry continued to be very poor (see Table 3). Even today, the industry has still failed to grasp this fundamental problem


Drug Discovery World Winter 2019/20


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68